Stock listing
OTC:BOVNF BioInvent International AB Stock
US listing (OTC) of BioInvent International AB · home listing Stockholm:BINV
Follow BioInvent International AB into a list and get an email when it puts out news.
Share price · OTC:BOVNF
$0.28 USD 0.00 (0.0%)
Close on Nov 11, 2026
- Day range
- $0.28 – $0.28 USDNov 11, 2026
- 52-week range
- $0.28 – $3.29 USDLowest and highest trades, Nov 12, 2025 – Nov 11, 2026
- Traded on an average day
- $126 USDMedian day 0 shares · 61 days with no trades · last 3 months, Aug 11, 2026 – Nov 11, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:BINV · Home | 2.75 SEK | -0.165 (-5.7%) | 215,209 | 2.91 | 2.945 | 2.66 | 2.915 | Close on Nov 16, 2026 |
| Frankfurt:BIX0 | €0.269 EUR | +0.003 (+1.1%) | — | €0.257 | €0.269 | €0.257 | €0.266 | Close on Nov 13, 2026 |
| OTC:BOVNF | $0.28 USD | 0.00 (0.0%) | — | $0.28 | $0.28 | $0.28 | $0.28 | Close on Nov 11, 2026 |
Daily closes
Last 3 months, Aug 11, 2026 – Nov 11, 2026 · OTC:BOVNF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.28 | 0.00 | 0.0% | $0.28 | $0.28 | $0.28 | 0 | |
| $0.28 | 0.00 | 0.0% | $0.28 | $0.28 | $0.28 | 0 | |
| $0.28 | -0.12 | -30.0% | $0.28 | $0.28 | $0.28 | 650 | |
| $0.40 | 0.00 | 0.0% | $0.40 | $0.40 | $0.40 | 2,500 | |
| $0.40 | 0.00 | 0.0% | $0.40 | $0.40 | $0.40 | 0 | |
| $0.40 | 0.00 | 0.0% | $0.40 | $0.40 | $0.40 | 0 | |
| $0.40 | -0.045 | -10.0% | $0.40 | $0.40 | $0.40 | 2,500 | |
| $0.444 | -0.166 | -27.2% | $0.549 | $0.549 | $0.444 | 7,000 | |
| $0.61 | 0.00 | 0.0% | $0.61 | $0.61 | $0.61 | 0 | |
| $0.61 | -2.679 | -81.5% | $0.753 | $0.93 | $0.61 | 5,000 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 | |
| $3.289 | 0.00 | 0.0% | $3.289 | $3.289 | $3.289 | 0 |
Splits
1 split · OTC:BOVNF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation |
- Ticker
- OTC:BOVNF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Oct 28, 2026
BioInvent International resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026
Latest earnings call · Feb 26, 2026
BioInvent International (Stockholm:BINV) Q4 2025 Earnings Call
Replay and transcript
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 49 slides
Calls
Replays
BioInvent International (Stockholm:BINV) Q4 2025 Earnings Call
Thu, Feb 26, 2026 · 8:00 AM ET
Watch TranscriptBioInvent International (Stockholm:BINV) Q3 2025 Earnings Call
Wed, Oct 29, 2025 · 9:00 AM ET
Watch Transcript
Latest news
BioInvent International resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026
Oct 28, 2026
Closed $3.29 (0.0%) on Oct 28, 2026
BioInvent International to present BI-1808 data in platinum-resistant recurrent ovarian cancer at ESMO 2026
Oct 18, 2026
Closed $3.29 (0.0%) on Oct 19, 2026
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
Jun 1, 2026
Closed $3.29 (0.0%) on Jun 1, 2026
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
May 12, 2026
Closed $3.29 (0.0%) on May 12, 2026
BioInvent International AB: Interim Report January - March 2026
Apr 29, 2026
Closed $3.29 (0.0%) on Apr 29, 2026
BioInvent International AB Publishes Annual Report 2025
Mar 31, 2026
Closed $3.29 (0.0%) on Mar 31, 2026
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
Mar 26, 2026
Closed $3.29 (0.0%) on Mar 26, 2026
Notice to Annual General Meeting in BioInvent International AB
Mar 24, 2026
Closed $3.29 (0.0%) on Mar 24, 2026
BioInvent International AB: Year-End Report January 1 - December 31, 2025
Feb 26, 2026
Closed $3.29 (0.0%) on Feb 26, 2026
Invitation to Presentation of BioInvent's Year-End Report 2025
Feb 26, 2026
Closed $3.29 (0.0%) on Feb 26, 2026
Financings
Rights offering of new shares with preferential rights
Oct 28, 2026 · US$43.28M
Announced: about SEK 430M · DNB Carnegie Investment Bank AB (publ)
Dealers: DNB Carnegie Investment Bank AB (publ) (lead)
Buyers: Redmile (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Van Herk (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Forbion (Subscription commitment; together with other existing shareholders approximately SEK 80 million); HealthInvest (Subscription commitment; together with other existing shareholders approximately SEK 80 million); DNB Bank ASA (Guarantee undertakings, with others, up to approximately SEK 270 million); Schonfeld Global Master Fund L.P. (Guarantee undertakings, with others, up to approximately SEK 270 million); Anavio Capital Partners LLP (Guarantee undertakings, with others, up to approximately SEK 270 million)
Insiders: Shareholding board members and management intend to subscribe approximately SEK 0.6 million in total, including pro rata from CEO Martin Welschof and Chairman Leonard Kruimer
Use of proceeds: Strengthen financial position and fund clinical development of priority programs, principally BI-1808 and BI-1206 in solid tumors
Decks
Investor Presentation (October 2026)
Investor deck · 49 slides · October 2026
Investor Presentation (October 2026)
Investor deck · 46 slides · October 2026
Investor Presentation (September 2026)
Investor deck · 47 slides · September 2026
Investor Presentation (May 2026)
Investor deck · 43 slides · May 27, 2026
BioInvent International AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 30 in all · newest Oct 28, 2026 · oldest 2025
- Calls
- 2 calls with a replay · 2 with a transcript · latest Feb 26, 2026
- Decks
- 23 decks · latest October 2026
Where BioInvent International AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:BINV · Home listing | Stockholm | Sweden | SEK |
| Aquis:BINVS | Aquis | United Kingdom | SEK |
| Stuttgart:BIX0 | Stuttgart | Germany | EUR |
| LS Exchange:A2QJRW | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2QJRW | Lang & Schwarz | Germany | EUR |
| gettex:BIX0 | gettex | Germany | EUR |
| Frankfurt:BIX0 | Frankfurt | Germany | EUR |
| Dusseldorf:BIX0 | Dusseldorf | Germany | EUR |
| LSIN:0H22 | LSIN | United Kingdom | SEK |
| Munich:BIX0 | Munich | Germany | EUR |
| OTC:BOVNF · This page | OTC | United States | USD |
| Aquis:BINVS | Aquis | United Kingdom | SEK |
| Turquoise:BINVS | Turquoise | United Kingdom | SEK |
Log in to ask 6ix AI your own questions about BioInvent International AB.